0001555192-21-000001.txt : 20211019 0001555192-21-000001.hdr.sgml : 20211019 20211019141657 ACCESSION NUMBER: 0001555192-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211019 DATE AS OF CHANGE: 20211019 EFFECTIVENESS DATE: 20211019 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elicio Therapeutics, Inc. CENTRAL INDEX KEY: 0001555192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452966790 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-417559 FILM NUMBER: 211330462 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-209-0056 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Vedantra Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120730 D 1 primary_doc.xml X0708 D LIVE 0001555192 Elicio Therapeutics, Inc. ONE KENDALL SQUARE BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 857-209-0050 DELAWARE Vedantra Pharmaceuticals, Inc. Corporation true Robert Connelly c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Mr. Connelly is the Chief Executive Officer of the Issuer. Julian Adams c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Dr. Adams is the Chairman of the Board of Directors of the Issuer. Daniel Geffken c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Mr. Geffken is the Interim Chief Financial Officer of the Issuer. Ofer Gonen c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Robert Ruffolo c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Christopher Haqq c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Dr. Haqq is an Executive Vice President, Head of Research and Development and the Chief Medical Officer of the Issuer. Carol Ashe c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Daphne Karydas c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Annette Matthies c/o Elicio, One Kendall Sq. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Ms. Matthies is the Chief Business Officer of the Issuer. Biotechnology Decline to Disclose 06b false 2021-10-04 false true true Convertible Notes false 0 15000000 2000000 13000000 false 1 0 0 0 true false Elicio Therapeutics, Inc. /s/ Robert Connelly Robert Connelly Chief Executive Officer 2021-10-19